Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2002, for Bristol-Myers Squibb Company. The filing was delayed due to a significant restatement of previously issued financial statements. The restatement was necessitated by errors in revenue recognition related to sales incentives and inventory buildup at U.S. pharmaceutical wholesalers, requiring the application of the consignment model for certain transactions. The delay initially triggered a breach of credit agreements, though the filing of this report cured the noncompliance, preventing the acceleration of debt.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 | Restated Nine Months Ended Sep 30, 2001 |
|---|---|---|---|
| Net Sales | $4,537 million | $13,325 million | $13,375 million |
| Net Earnings | $357 million | $1,692 million | $3,550 million |
| Earnings Per Share (Diluted) | $0.18 | $0.87 | $1.80 |
| Operating Cash Flow | N/A | $264 million | $3,436 million |
| Cash and Equivalents | $3,562 million | $3,562 million | $5,500 million (Dec 31, 2001) |
| Long-Term Debt | $6,204 million | $6,204 million | $6,237 million (Dec 31, 2001) |
| Working Capital | $2,435 million | $2,435 million | $2,140 million (Dec 31, 2001) |
Note: Working Capital calculated as Total Current Assets ($10,573M) minus Total Current Liabilities ($8,138M).
Material Changes vs. Prior Period
- Revenue Recognition Restatement: The company restated prior periods to correct revenue recognition errors. Approximately $1,125 million of sales recognized in the nine months ended September 30, 2002, were restated from prior periods. This adjustment significantly reduced reported earnings for 2001 and 2002 compared to previously announced figures.
- Profitability Decline: Net earnings for the nine months ended September 30, 2002, dropped to $1,692 million from $3,550 million in the prior year (restated). This decline is primarily due to litigation charges, asset impairments, and the impact of the revenue restatement.
- Cash Flow Contraction: Net cash provided by operating activities plummeted to $264 million in 2002 from $3,436 million in 2001. This was driven by a $2,046 million cash outflow for income taxes (related to the Clairol sale) and a decrease in deferred revenue from consignment sales.
- Segment Performance: Pharmaceuticals sales decreased 3% year-over-year (restated) due to generic competition for key products (GLUCOPHAGE, TAXOL, BUSPAR) and the workdown of wholesaler inventories. Conversely, the Other Healthcare segment saw earnings increase due to the DuPont acquisition.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and Charges
- Litigation Settlements: The company recorded a $569 million litigation charge in Q3 2002 (totaling $659 million for the nine months), primarily related to proposed settlements for BUSPAR ($535 million) and TAXOL ($135 million) antitrust litigation.
- Asset Impairment: A $379 million pre-tax charge was recorded for an other-than-temporary decline in the market value of the company's equity investment in ImClone Systems.
- Restructuring: The company recorded a net benefit of $10 million for the nine months, resulting from $136 million in new charges offset by $146 million in reductions of prior period reserves.
Risks and Contingencies
- Legal Proceedings: Significant pending litigation includes antitrust suits regarding BUSPAR and TAXOL, securities class actions regarding VANLEV and wholesaler inventory practices, and investigations by the SEC and U.S. Attorney's Office. While settlements have been proposed for BUSPAR and TAXOL, final approval is not guaranteed.
- Internal Controls: Independent auditors identified two "material weaknesses" in internal controls related to accounting and financial reporting. Management has hired a new CFO, restaffed the controller position, and implemented new certification processes to address these issues.
- Wholesaler Inventory: The company is in the process of working down excess wholesaler inventories, which is expected to be substantially completed by the end of 2003. This workdown continues to impact sales comparability.
Outlook
Management expects the orderly workdown of wholesaler inventories to be substantially completed by the end of 2003. The company is rebalancing its R&D pipeline to focus on late-stage development and near-term product launches. Credit ratings were downgraded to Aa2/AA in 2002 and remain under review by Moody's.
Investor Verification Checklist
- Restatement Impact: Verify the full extent of the revenue restatement on prior years' earnings and the specific criteria used to apply the consignment model to Cardinal and McKesson.
- Litigation Finality: Confirm the status of the proposed BUSPAR and TAXOL settlements, specifically whether court approvals and insurer agreements have been finalized.
- Internal Controls Remediation: Assess the progress of the new internal control measures and the effectiveness of the new CFO and compliance officer in preventing future accounting errors.
- ImClone Exposure: Review the remaining value of the ImClone investment and the potential impact of FIN 46 (Variable Interest Entities) on future consolidation requirements.
- Cash Flow Sustainability: Analyze the sustainability of operating cash flows given the one-time tax outflows and the ongoing impact of inventory workdowns on deferred revenue.